Marinus Pharmaceuticals (MRNS) 8-K Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder

Exhibit 99.2

 

©2022 Marinus Pharmaceuticals. All Rights Reserved I Dosing Assumptions* Avg. age: 4.5 years old Transparent, weight - based pricing strategy Avg. weight: ~16 kg Avg. daily dose: ~50 – 55 (mg/kg) Marinus is committed to no price increases through end of 2023 Informed Access & Pricing Strategy 1 *Based on Marigold Trial and market research Pricing & Access Decisions Informed by Marinus values COMMUNITY First & only FDA approved treatment for seizures associated with CDD COMMITMENT Patient assistance programs will support access and affordability for CDD patients INNOVATION Committed to innovation and building a scalable business model to help more patients in the future Bottle WAC: $2,425 / 110mL Avg. Annual WAC: ~$133,000